Cisplatin for Lung Cancer

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Oncosite - Centro de Pesquisa Clinica E Oncologia, Ijua, BrazilLung Cancer+1 MoreCisplatin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether adding a new drug to standard platinum-based chemotherapy helps people with lung cancer live longer.

Eligible Conditions
  • Squamous Cell Lung Cancer
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
Cisplatin
1
INCB106385
1
Pemigatinib

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Approximately 4.5 years

Approximately 4.5 years
Progression-free survival (PFS)
Approximately 4.5 years.
Cmax of INCMGA00012 when administered with chemotherapy
Duration of response (DOR)
Number of treatment-emergent adverse events
Objective response rate (ORR)
Overall survival (OS)
Year 5
AUC of INCMGA00012 when administered with chemotherapy

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Cisplatin
1
INCB106385
2
Pemigatinib

Side Effects for

Gemcitabine Plus Cisplatin (GC)
51%Neutropenia
47%Leukopenia
46%Nausea
43%Vomiting
35%Anaemia
31%Decreased appetite
26%Haemoglobin decreased
26%Fatigue
25%Constipation
25%White blood cell count decreased
24%Neutrophil count decreased
19%Alanine aminotransferase increased
13%Platelet count decreased
12%Rash
10%Aspartate aminotransferase increased
10%Thrombocytopenia
9%Blood sodium decreased
8%Hypokalaemia
7%Pyrexia
7%Insomnia
6%Blood creatinine increased
6%Hyponatraemia
6%Cough
6%Lymphopenia
6%Diarrhoea
6%Dyspepsia
6%Red blood cell count decreased
4%Dizziness
2%Bone marrow failure
1%Cerebral infarction
1%Embolism venous
1%Superior vena cava syndrome
1%Pulmonary embolism
1%Dyspnoea
1%Ischaemic stroke
This histogram enumerates side effects from a completed 2012 Phase 3 trial (NCT01005680) in the Gemcitabine Plus Cisplatin (GC) ARM group. Side effects include: Neutropenia with 51%, Leukopenia with 47%, Nausea with 46%, Vomiting with 43%, Anaemia with 35%.

Trial Design

4 Treatment Groups

Placebo + chemotherapy (nonsquamous NSCLC)
1 of 4
Placebo + chemotherapy (squamous NSCLC)
1 of 4
INCMGA00012 + chemotherapy (nonsquamous NSCLC)
1 of 4
INCMGA00012 + chemotherapy (squamous NSCLC)
1 of 4

Active Control

Experimental Treatment

600 Total Participants · 4 Treatment Groups

Primary Treatment: Cisplatin · Has Placebo Group · Phase 3

INCMGA00012 + chemotherapy (nonsquamous NSCLC)Experimental Group · 4 Interventions: Cisplatin, Retifanlimab, Carboplatin, Pemetrexed · Intervention Types: Drug, Drug, Drug, Drug
INCMGA00012 + chemotherapy (squamous NSCLC)Experimental Group · 4 Interventions: Retifanlimab, nab-Paclitaxel, Carboplatin, Paclitaxel · Intervention Types: Drug, Drug, Drug, Drug
Placebo + chemotherapy (nonsquamous NSCLC)ActiveComparator Group · 4 Interventions: Cisplatin, Placebo, Carboplatin, Pemetrexed · Intervention Types: Drug, Drug, Drug, Drug
Placebo + chemotherapy (squamous NSCLC)ActiveComparator Group · 4 Interventions: Placebo, nab-Paclitaxel, Carboplatin, Paclitaxel · Intervention Types: Drug, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cisplatin
FDA approved
Retifanlimab
Not yet FDA approved
Paclitaxel
FDA approved
Carboplatin
FDA approved
Pemetrexed
FDA approved
Paclitaxel
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 4.5 years

Who is running the clinical trial?

Zai Lab (Shanghai) Co., Ltd.Industry Sponsor
23 Previous Clinical Trials
2,488 Total Patients Enrolled
Incyte CorporationLead Sponsor
323 Previous Clinical Trials
46,421 Total Patients Enrolled
Incyte Medical MonitorStudy DirectorIncyte Corporation
7 Previous Clinical Trials
569 Total Patients Enrolled
Mark CornfieldStudy DirectorIncyte Corporation
1 Previous Clinical Trials
300 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

What are the short and long term effects of Cisplatin?

"Cisplatin has received a score of 3 from our Power team. This is due to the fact that Cisplatin is in Phase 3 clinical trials, meaning there is existing data supporting both its efficacy and safety." - Anonymous Online Contributor

Unverified Answer

What are some of the conditions that Cisplatin is used to treat?

"Cisplatin is typically used to treat unresectable thymoma, but it has also been found helpful in treating mesotheliomas, refractory advanced non small cell lung cancer (nsclc), and other conditions." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top